Orthopedic surgery ·
Standardized PRP pathway eases knee osteoarthritis pain; robotic MIS-TLIF trial shows earlier recovery only; FDA clears pediatric femoral nail
Listen to this post
read by AI voices · all episodesTHE SHORT READ
A three-hospital randomized trial of 240 patients found a standardized platelet-rich plasma pathway improved 12-month knee osteoarthritis pain more than physician-directed platelet-rich plasma care.
A randomized trial of 128 patients found robot-assisted minimally invasive lumbar fusion gave earlier recovery and better screw placement than open fusion but no midterm clinical gain, and the Food and Drug Administration (FDA) cleared a pediatric femoral nail.
THE DETAILS
- Research Oct 26, 2026In a three-hospital, double-blind randomized trial of 240 patients with Kellgren-Lawrence grade I and II knee osteoarthritis, published Oct. 26 in The American Journal of Sports Medicine, a standardized platelet-rich plasma (PRP) pathway improved 12-month visual analog scale pain more than physician-directed PRP care (mean difference -2.98; 95% CI -3.64 to -2.32). The pathway combined patient selection, leukocyte-poor PRP, ultrasound-guided injection and staged rehabilitation. Adverse events occurred in 14.8% versus 31.9% of patients. The authors said the trial, which had no placebo group, does not establish PRP efficacy.
- Technology Oct 29, 2026In a single-center, assessor-blinded randomized trial in China published Oct. 29 in the Journal of Robotic Surgery, 128 patients with lumbar degenerative disease were assigned 1:3 to robot-assisted minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) or fluoroscopy-guided open TLIF. The two-week Oswestry Disability Index, the primary end point, favored the robot (mean difference -3.27; 95% CI -5.98 to -0.56; P = .019), but the gap was below the 10-point target and not significant at three months. Grade A screw placement was 98.9% versus 94.5% (P = .037); operative time was longer and fusion rates were similar.Sources: Journal of Robotic Surgery, PubMed
- FDA Oct 27, 2026OrthoPediatrics said Oct. 27 that the Food and Drug Administration (FDA) granted 510(k) clearance to its Pediatric Nailing Platform Femur Retrograde Nail System for pediatric femoral trauma and deformity correction, and that the first procedures with the system were completed. The company said the system, designed for pediatric anatomy, includes anatomic nails for trauma and straight nails for deformity in diameters of 7 mm to 11 mm. It plans a limited market release for the rest of 2026 and broader commercialization in 2027.Source: OrthoPediatrics (via BioSpace)
The weekly innovation roundup for orthopedic surgery, published every Sunday for the week before; every item links to its sources. Latest orthopedic surgery news · All specialties